Insight Wealth Strategies LLC Has $4.17 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Insight Wealth Strategies LLC increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 230.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,096 shares of the company's stock after purchasing an additional 7,041 shares during the quarter. Insight Wealth Strategies LLC's holdings in IDEXX Laboratories were worth $4,174,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. International Assets Investment Management LLC raised its stake in shares of IDEXX Laboratories by 52,746.0% in the 3rd quarter. International Assets Investment Management LLC now owns 528,460 shares of the company's stock worth $2,669,890,000 after buying an additional 527,460 shares in the last quarter. Clearbridge Investments LLC raised its position in IDEXX Laboratories by 696.0% in the second quarter. Clearbridge Investments LLC now owns 352,814 shares of the company's stock worth $171,891,000 after acquiring an additional 308,493 shares in the last quarter. Vontobel Holding Ltd. grew its position in IDEXX Laboratories by 3,325.0% in the third quarter. Vontobel Holding Ltd. now owns 220,159 shares of the company's stock worth $111,229,000 after buying an additional 213,731 shares during the last quarter. American Century Companies Inc. increased its holdings in shares of IDEXX Laboratories by 46.0% in the second quarter. American Century Companies Inc. now owns 562,764 shares of the company's stock valued at $274,179,000 after buying an additional 177,226 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its stake in shares of IDEXX Laboratories by 4,193.1% during the 2nd quarter. 1832 Asset Management L.P. now owns 128,491 shares of the company's stock worth $62,601,000 after acquiring an additional 125,498 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insider Activity

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now directly owns 905 shares of the company's stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 2.11% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 3.3 %

IDXX traded up $13.63 during trading on Monday, reaching $429.16. 627,098 shares of the stock traded hands, compared to its average volume of 447,366. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. IDEXX Laboratories, Inc. has a fifty-two week low of $398.50 and a fifty-two week high of $583.39. The stock's 50-day simple moving average is $424.43 and its two-hundred day simple moving average is $462.26. The stock has a market cap of $35.14 billion, a price-to-earnings ratio of 41.38, a price-to-earnings-growth ratio of 3.94 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The business had revenue of $975.50 million during the quarter, compared to analysts' expectations of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.53 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IDXX. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a research note on Thursday, October 10th. Barclays dropped their target price on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price target for the company. Finally, JPMorgan Chase & Co. lowered their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Two analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $539.63.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.